FT Options’s Heron Therapeutics HRTX Stock Holding History

FT Options’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-29,937	Closed	-$516K	–	301
2016 Q3	$516K	Buy	29,937 +24,781	+481%	+$460K	0.41%	52
2016 Q2	$93K	Buy	+5,156	New	+$101K	0.08%	159
2016 Q1	–	Sell	-71,049	Closed	-$1.4M	–	312
2015 Q4	$1.9M	Buy	+71,049	New	+$1.9M	1.4%	15

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

FT Options's HRTX Position: Q4 2016 in Review

FT Options sold out of Heron Therapeutics (HRTX) in Q4 2016, closing a stake of 29,937 shares — an estimated $516K sold.

FT Options first reported a position in HRTX in Q4 2015 and held it in 3 quarters. The position peaked at $1.9M in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

FT Options reported no remaining Heron Therapeutics position as of Q4 2016 after selling out during the quarter.
FT Options sold 29,937 Heron Therapeutics shares in Q4 2016, an estimated $516K.
FT Options first reported a position in Heron Therapeutics in Q4 2015 and held it in 3 quarters.
FT Options's Heron Therapeutics position peaked at $1.9M in Q4 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.